Results 201 to 210 of about 99,222 (285)
Ceramide-Phospholipid Risk Score Associates With Cardiovascular Events and Is Lowered by Atorvastatin, Simvastatin, and Anti-PCSK9 Treatments. [PDF]
J Cardiovasc PharmacolHilvo M, Witoslawska A, Witoslawska A, Lääperi M, Jylhä A, Lyytikäinen LP, Päivä H, Laurikka J, März W, Karhunen PJ, Lehtimäki T, Laaksonen R. +11 moreeuropepmc +1 more sourceAngiogenic and Stromal Remodeling Associated With Aggressive Fibrosarcomatous Dermatofibrosarcoma Protuberans
Cancer Science, EarlyView.FS‐DFSP exhibits coordinated angiogenic and stromal remodeling characterized by immature vascular features, CAF accumulation, and enhanced macrophage infiltration. VEGFA, CCL2, and CXCR4 may contribute to this tumor‐promoting microenvironment. ABSTRACT
Although collagen type 1 alpha 1 (COL1A1)–platelet‐derived growth factor B‐chain (PDGFB) gene fusion ...Sakura Shiraishi, Takeshi Iwasaki, Ken Takigawa, Kengo Kawaguchi, Hiroki Sonoda, Kohta Miyawaki, Takumi Tomonaga, Taro Mori, Makoto Endo, Koji Kato, Yasuharu Nakashima, Yoshinao Oda +11 morewiley +1 more sourceAdherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 226-238, March 2025.In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.Bernardo Sousa‐Pinto, Elísio M. Costa, Rafael José Vieira, Ludger Klimek, Wienczyslawa Czarlewski, Oliver Pfaar, Anna Bedbrook, Rita Amaral, Luisa Brussino, Violeta Kvedariene, Desiree E. Larenas‐Linnemann, Tomohisa Iinuma, Nhân Pham‐Thi, Frederico S. Regateiro, Luis Taborda‐Barata, Maria Teresa Ventura, Ignacio J. Ansotegui, Karl C. Bergmann, G. Walter Canonica, Victoria Cardona, Lorenzo Cecchi, Ivan Cherrez‐Ojeda, Cemal Cingi, Alvaro A. Cruz, Stefano Del Giacco, Philippe Devillier, Wytske J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Piotr Kuna, Helga Kraxner, Daniel Laune, Renaud Louis, Michael Makris, Mario Morais‐Almeida, Ralph Mösges, Marek Niedoszytko, Nikolaos G. Papadopoulos, Vincenzo Patella, Ana Margarida Pereira, Sietze Reitsma, Karla Robles‐Velasco, Philip W. Rouadi, Boleslaw Samolinski, Milan Sova, Sanna K. Toppila‐Salmi, Joaquin Sastre, Arunas Valiulis, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, Joao A. Fonseca, Jean Bousquet, the MASK‐air think tank, Josep M. Anto, Maciej Kupczyk, Marek Kulus, Nicolas Roche, Nicola Scichilone, Rute Almeida, Sinthia Bosnic‐Anticevich, Fulvio Braido, Claudia Chaves Loureiro, Govert de Vries, Antonio F. M. Giuliano, Cristina Jácome, Igor Kaidashev, Gilles Louis, Olga Lourenço, Mika Makela, Marcus Maurer, Joaquim Mullol, Rachel Nadif, Robyn O’Hehir, Yoshitaka Okamoto, Markus Ollert, Heidi Olze, Benoit Pétré, Francesca Puggioni, Jan Romantowski, Daniela Rivero‐Yeverino, Monica Rodriguez‐Gonzalez, Ana Sá‐Sousa, Marine Savouré, Faradiba S. Serpa, Mohamed H. Shamji, Aziz Sheikh, Charlotte Suppli Ulrik, Mikhail Sofiev, Annette Sperl, Ana Todo‐Bom, Ioanna Tsiligianni, Erkka Valovirta, Michiel van Eerd, Hubert Blain, Louis‐Philippe Boulet, Guy Brusselle, Roland Buhl, Denis Charpin, Thomas Casale, Tomas Chivato, Jaime Correia‐de‐Sousa, Christopher Corrigan, Frédéric de Blay, Mark Dykewicz, Alessandro Fiocchi, Mattia Giovannini, Ewa Jassem, Marek Jutel, Thomas Keil, Stefania La Grutta, Brian Lipworth, Alberto Papi, Jean‐Louis Pépin, Santiago Quirce, Carlos Robalo Cordeiro, Maria J. Torres, Omar S. Usmani, Matteo Bonini, Brigita Gradauskiene, Christopher Brightling +121 morewiley +1 more sourceSubcutaneous Allergen Immunotherapy With Thermosensitive Hydrogel and Recombinant Birch Pollen Allergen Variant, a Randomised Controlled Trial
Clinical &Experimental Allergy, EarlyView.A Phase 1, randomised, placebo‐controlled, dose‐escalation trial was performed with 30 birch pollen allergic subjects treated with DM‐101PX, that contains a recombinant hypoallergenic variant of Bet v 1 formulated with poloxamer 338 thermosensitive hydrogel.Anna Nilson, Patricia Couroux, Jaana Haka, Silja Halme, Pekka Mattila, R. J. Joost van Neerven, Rolien Pels‐Rijcken, Janneke Ruinemans‐Koerts, Yvonne Schmidt‐Hieltjes, Anne Marie Salapatek, Kati Sallinen, Kristiina Takkinen, Daphne Tsitoura, Dirk‐Jan Opstelten, Juha Rouvinen +14 morewiley +1 more sourceGenetic Testing Unveils a Novel Thrombospondin‐1 Domain Containing Protein 1 Gene Variant as the Cause of Chronic Edema in a 79‐Year‐Old Woman
Clinical Genetics, EarlyView.A 79‐year‐old woman with lifelong peripheral edema and an affected sister was found to harbor a novel homozygous THSD1 splice‐site variant. Reduced THSD1 expression in dermal endothelial cells supported the possibility that this variant contributes to chronic hereditary edema.Eiko Amo, Takafumi Toyohara, Naoya Saijo, Satoko Sato, Jun Takayama, Yoshiko Suto, Yuji Noguchi, Sosuke Kinomura, Yusuke Ishizuka, Shun Watanabe, Koichi Kikuchi, Rui Makino, Mai Yoshida, Yuji Oe, Tasuku Nagasawa, Koji Okamoto, Takehiro Suzuki, Mariko Miyazaki, Shinya Kawaguchi, Takashi Suzuki, Takaaki Abe, Shigeo Kure, Atsuo Kikuchi, Tetsuhiro Tanaka +23 morewiley +1 more source